Braidwell LP Has $40.50 Million Position in TransMedics Group, Inc. $TMDX

Braidwell LP increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 85.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 609,715 shares of the company’s stock after acquiring an additional 280,324 shares during the quarter. TransMedics Group makes up about 1.5% of Braidwell LP’s portfolio, making the stock its 25th largest position. Braidwell LP owned approximately 1.76% of TransMedics Group worth $40,497,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also bought and sold shares of the stock. Headlands Technologies LLC bought a new stake in TransMedics Group in the second quarter valued at $1,634,000. Flputnam Investment Management Co. bought a new position in shares of TransMedics Group during the 2nd quarter worth about $77,000. Van ECK Associates Corp grew its stake in shares of TransMedics Group by 56.4% in the 2nd quarter. Van ECK Associates Corp now owns 3,241 shares of the company’s stock valued at $215,000 after buying an additional 1,169 shares during the period. Wellington Management Group LLP grew its stake in shares of TransMedics Group by 6.1% in the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock valued at $34,271,000 after buying an additional 29,500 shares during the period. Finally, RB Capital Management LLC bought a new stake in TransMedics Group in the 2nd quarter valued at about $337,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TMDX. Canaccord Genuity Group reaffirmed a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research note on Tuesday, June 30th. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Piper Sandler reaffirmed an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Finally, Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $124.18.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This trade represents a 36.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by corporate insiders.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $84.29 on Thursday. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of 21.67 and a beta of 1.90. The company has a fifty day moving average price of $79.53 and a 200-day moving average price of $92.53.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter in the prior year, the company earned $0.92 EPS. The business’s revenue for the quarter was up 20.7% on a year-over-year basis. As a group, equities research analysts predict that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.